| Japanese |
|---|
| Title | 前立腺癌患者における前立腺酸フォスファターゼ (PAP) と骨シンチグラフィの関係 |
|---|
| Subtitle | 原著 |
|---|
| Authors | 相澤卓*, 伊藤貴章*, 辻野進*, 並木一典*, 三木誠* |
|---|
| Authors(kana) | |
|---|
| Organization | *東京医科大学泌尿器科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 29 |
|---|
| Number | 11 |
|---|
| Page | 1277-1283 |
|---|
| Year/Month | 1992/11 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」PAP(prostate acid phosphatase)の測定値が前立腺癌の骨転移の病勢を敏感に反映するなら, 骨シンチグラフィを必ずしも短期間に頻回に行う必要はない. この点を明らかにすべくretrospectiveに検討した. 対象は最近5年間に経験した前立腺癌患者のうち骨シンチグラフィを実施した77例で, そのうち2回以上骨シンチグラフィを行った30例を中心に骨シンチグラムの変化とPAP値の変動を検討した, いずれも抗男性ホルモン剤で治療されていた. 骨シンチグラムの変化とPAP値の推移が一致したものは27例であり, とくにマーカー値が短期間に急上昇した例で骨シンチグラムの悪化所見がよく一致していた. 今回の検討に限れば, 前立腺癌患者のfollow upにあたっては, 骨シンチグラフィを必ずしも3か月ごとなど定期的に実施する必要はなく, 腫瘍マーカーが短期間に急上昇したときに実施すればよいと考えられる. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | Prostatic cancer, Prostate acid phosphatase, Bone scintigraphy. |
|---|
| English |
|---|
| Title | Relation between Serum PAP (Prostate Acid Phosphatase) and Bone Scintigraphy in Prostatic Cancer |
|---|
| Subtitle | Original Articles |
|---|
| Authors | Taku AIZAWA, Takaaki ITOH, Susumu TSUJINO, Kazunori NAMIKI, Makoto MIKI |
|---|
| Authors(kana) | |
|---|
| Organization | Department of Urology, Tokyo Medical College |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 29 |
|---|
| Number | 11 |
|---|
| Page | 1277-1283 |
|---|
| Year/Month | 1992/11 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary]Seventy-seven patients with prostatic cancer were treated at our department in the last 5 years. Of these patients 30 cases were followed by bone scintigraphy and serum PAP. In 27 follow-up scintigraphy procedures changes of bone scintigraphy corresponded to changes in serum PAP levels Changes of PAP levels did not always correspond to changes of scintigraphy, but almost all cases in which the level of PAP increased in a short period showed progression of bone metastasis. A 3-month interval between bone scintigraphy procedure in stage D2 prostatic cancer patients is generally recommended. However, we think that in prostatic cancer patients follow-up bone scintigraphy at regular short intervals is unnecessary if there is no change in serum PAP levels, symptoms or physical condition. Bone scintigraphy should be performed when the tumor marker changes rapidly or when any physical symptom appears. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | Prostatic cancer, Prostate acid phosphatase, Bone scintigraphy. |
|---|